Thank you to our Foundational and Sustaining members
ROCHESTER, Minn., December 11, 2019 – Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced the appointment of experienced life sciences investors Edwin M. Kania, Jr. and Nathan L. Stacy to the Company’s board of directors. Mr. Kania was named Chairman of the Board. Mr. […]
Phase 2 trial will evaluate combination of PD-1 inhibitor Libtayo® (cemiplimab-rwlc) and oncolytic virus Voyager-V1; preclinical research collaboration will explore new oncolytic virus treatments Vyriad to receive upfront payment and equity investment from Regeneron TARRYTOWN, N.Y., and ROCHESTER, Minn. (November 6, 2019) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Vyriad, Inc. today announced a research collaboration and option […]
MINNEAPOLIS, July 17, 2019 /PRNewswire/ ‐‐ Bio‐Techne Corporation (NASDAQ: TECH) today announced the launch of a new 8‐Plex cartridge format for the ProteinSimple™‐branded Ella™ automated immunoassay platform. This new cartridge format analyzes 32 samples for eight distinct analytes, bringing higher multiplex capabilities to the Ella platform. The 32×8 cartridge for Ella enables users to build […]
On March 21st, Boston Scientific announced its intent to acquire Medical Alley-based NxThera, a medical device company developing the Rezūm system, a revolutionary, safe, and cost-effective minimally invasive treatment option for men suffering from benign prostatic hyperplasia (BPH). “We are excited to announce this agreement with Boston Scientific,” said Bob Paulson, president and chief executive […]